# SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

> **NCT06674109** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Gout and Hyperuricemia

## Interventions

- **DRUG:** Empagliflozin 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06674109
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674109, "SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06674109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*